tirzepatide amble Flex-Dose 1 mL Injectable 10 mg/mL Lilly releases Zepbound® (tirzepatide) single-dose

Given the success of these medications for weight loss in the general population, it makes sense to wonder if GLP-1s for menopause might be a good fit

Your Metabolism Metabolism is a crucial calorie-burning driver

Whether youre aiming for physical fitness, hormonal balance, immune system boosts or mental wellbeing, weve got the right solution to fit your needs

No structured comorbidity multi-select diabetes, hypertension, hyperlipidemia, sleep apnea are bucketed into the free-text past medical problems field

(2022) 71:335-OR

Other adverse events Common (1% to 10%): Pyrexia, increased energy, fatigue [Ref] Gastrointestinal Very common (10% or more): Dry mouth (36%), upper abdominal pain (12%) Common (1% to 10%): Vomiting, nausea, diarrhea, constipation, gastroenteritis [Ref] Metabolic Very common (10% or more): Decreased appetite (39%), decreased weight (16.3%) Common (1% to 10%): Anorexia [Ref] Nervous system Very common (10% or more): Headache (20.3%) Common (1% to 10%): Dizziness, somnolence, tremor, paresthesia, nightmare, dyskinesia, seizures, psychomotor hyperactivity Postmarketing reports : Dyskinesia [Ref] Psychiatric Very common (10% or more): Insomnia (27%), irritability (10%) Common (1% to 10%): Tic, anxiety, agitation, erectile dysfunction, decreased libido, affect lability, feeling jittery, restlessness, aggression, initial insomnia, bruxism Uncommon (0.1% to 1%): Logorrhea, depression, dysphoria, euphoria, dermatillomania, mania, hallucinations Postmarketing reports : Libido changes, frequent or prolonged erections, psychotic episodes [Ref] Dermatologic Common (1% to 10%): Rash, hyperhidrosis, pruritus Uncommon (0.1% to 1%): Urticaria Postmarketing reports : Stevens-Johnson Syndrome, angioedema [Ref] Cardiovascular Common (1% to 10%): Increased blood pressure, increased heart rate, tachycardia, palpitations Uncommon (0.1% to 1%): Raynaud's phenomenon Postmarketing reports : Cardiomyopathy [Ref] Hypersensitivity Uncommon (0.1% to 1%): Hypersensitivity Postmarketing reports : Anaphylactic reaction [Ref] Genitourinary Common (1% to 10%): Urinary tract infection [Ref] Ocular Uncommon (0.1% to 1%): Mydriasis, blurred vision Postmarketing reports : Diplopia, visual accommodation difficulties [Ref] Hepatic Postmarketing reports : Eosinophilic hepatitis [Ref] Musculoskeletal Postmarketing reports : Rhabdomyolysis [Ref] Respiratory Common (1% to 10%): Dyspnea, oropharyngeal pain [Ref] References 1